找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Cancer Therapeutics; Experimental and Cli Beverly A. Teicher Book 1997 Springer Science+Business Media New York 1997 DNA.angiogenesis.cance

[復(fù)制鏈接]
查看: 28546|回復(fù): 57
樓主
發(fā)表于 2025-3-21 17:49:27 | 只看該作者 |倒序瀏覽 |閱讀模式
書目名稱Cancer Therapeutics
副標題Experimental and Cli
編輯Beverly A. Teicher
視頻videohttp://file.papertrans.cn/222/221212/221212.mp4
叢書名稱Cancer Drug Discovery and Development
圖書封面Titlebook: Cancer Therapeutics; Experimental and Cli Beverly A. Teicher Book 1997 Springer Science+Business Media New York 1997 DNA.angiogenesis.cance
描述Cancer drug discovery has been and continues to be a process of ingenuity, serendip- ity, and dogged determination. In an effort to develop and discover better therapies against cancer, investigators all over the world have increased our knowledge of cell biology, biochemistry, and molecular biology. The goal has been to define therapeuti- cally exploitable differences between normal and malignant cells. The result has been an increased understanding of cellular and whole-organism biology and an increased respect for the flexibility and resiliency ofbiologically systems. Thus, as some new therapeutic targets have been defined and new therapeutic strategies have been attempted, so have some new biological hurdles resulting from tumor evasion of the intended therapeutic attack been discovered. Historically, anticancer drugs have originated from all available chemical sources. Synthetic molecules from the chemical industry, especially dyestuffs and warfare agents, and natural products from plants, microbes, and fungi have all been potential sources of pharmaceuticals, including anticancer agents. There is no shortage of molecules; the challenge has been and continues to be methods of
出版日期Book 1997
關(guān)鍵詞DNA; angiogenesis; cancer; cancer treatment; cytokine; cytokines; drug; drug development; drug discovery; gen
版次1
doihttps://doi.org/10.1007/978-1-59259-717-8
isbn_softcover978-1-61737-046-5
isbn_ebook978-1-59259-717-8Series ISSN 2196-9906 Series E-ISSN 2196-9914
issn_series 2196-9906
copyrightSpringer Science+Business Media New York 1997
The information of publication is updating

書目名稱Cancer Therapeutics影響因子(影響力)




書目名稱Cancer Therapeutics影響因子(影響力)學(xué)科排名




書目名稱Cancer Therapeutics網(wǎng)絡(luò)公開度




書目名稱Cancer Therapeutics網(wǎng)絡(luò)公開度學(xué)科排名




書目名稱Cancer Therapeutics被引頻次




書目名稱Cancer Therapeutics被引頻次學(xué)科排名




書目名稱Cancer Therapeutics年度引用




書目名稱Cancer Therapeutics年度引用學(xué)科排名




書目名稱Cancer Therapeutics讀者反饋




書目名稱Cancer Therapeutics讀者反饋學(xué)科排名




單選投票, 共有 1 人參與投票
 

0票 0.00%

Perfect with Aesthetics

 

0票 0.00%

Better Implies Difficulty

 

0票 0.00%

Good and Satisfactory

 

1票 100.00%

Adverse Performance

 

0票 0.00%

Disdainful Garbage

您所在的用戶組沒有投票權(quán)限
沙發(fā)
發(fā)表于 2025-3-21 23:42:42 | 只看該作者
板凳
發(fā)表于 2025-3-22 00:55:04 | 只看該作者
The Enediynes-related and idiosyncratic types (.), and led to curtailment of preclinical and clinical studies of this drug in this country, and efforts to synthesize and isolate novel enediyne compounds that might not engender these difficulties. This chapter deals with the enediynes as a class. Because of its r
地板
發(fā)表于 2025-3-22 07:53:53 | 只看該作者
Book 1997ecules from the chemical industry, especially dyestuffs and warfare agents, and natural products from plants, microbes, and fungi have all been potential sources of pharmaceuticals, including anticancer agents. There is no shortage of molecules; the challenge has been and continues to be methods of
5#
發(fā)表于 2025-3-22 10:51:27 | 只看該作者
2196-9906 een potential sources of pharmaceuticals, including anticancer agents. There is no shortage of molecules; the challenge has been and continues to be methods of 978-1-61737-046-5978-1-59259-717-8Series ISSN 2196-9906 Series E-ISSN 2196-9914
6#
發(fā)表于 2025-3-22 15:10:03 | 只看該作者
7#
發(fā)表于 2025-3-22 19:42:39 | 只看該作者
8#
發(fā)表于 2025-3-23 01:01:45 | 只看該作者
https://doi.org/10.1007/978-81-322-2089-3-related and idiosyncratic types (.), and led to curtailment of preclinical and clinical studies of this drug in this country, and efforts to synthesize and isolate novel enediyne compounds that might not engender these difficulties. This chapter deals with the enediynes as a class. Because of its r
9#
發(fā)表于 2025-3-23 05:11:46 | 只看該作者
10#
發(fā)表于 2025-3-23 09:15:56 | 只看該作者
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-10 00:11
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
青神县| 玉溪市| 怀安县| 汝南县| 大英县| 广宁县| 湟中县| 囊谦县| 册亨县| 柞水县| 富平县| 德钦县| 普兰县| 靖边县| 微山县| 泰兴市| 清流县| 友谊县| 新竹市| 成都市| 崇义县| 行唐县| 稻城县| 界首市| 延庆县| 新宁县| 赤城县| 盱眙县| 两当县| 临汾市| 安阳县| 亚东县| 银川市| 府谷县| 万源市| 六枝特区| 荆州市| 湄潭县| 宜章县| 诸暨市| 沂水县|